Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed ...

Eli Lilly's injectable GLP-1 agonist medicines for obesity and diabetes drove 56% growth in first-quarter sales, but ...

From chip giant NVIDIA agreeing a $2 billion partnership with AI cloud provider Nebius, to Roche ramping up its investment in ...

After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate ...

New guidance from reimbursement authority NICE has recommended Rystiggo (rozanolixizumab) for people with gMG who test ...

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, after Norgine's ...

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain uncertain ...

Summit Therapeutics has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to show an improvement in overall survival in a lung cancer trial. New ...

Anthropic has launched Claude for Healthcare, a suite of AI tools for health systems, payers, and patients, in the latest part of its push into the health category. The announcement – made at the ...

The latest biotech to emerge from the Flagship Pioneering incubator – Lila Sciences – has emerged with $200 million in seed financing to advance its vision of artificial intelligence-powered, fully ...

Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...